Related Experiment Videos
[Treatment and prevention of pneumococcal pneumonia]
Paul Léophonte1, Julien Mazières
1Service de pneumologie, hôpital Rangueil-Larrey, TSA 50032, 31059 Toulouse. leophonte.p@chu-toulouse.fr
Abstract:
Streptococcus pneumoniae is the most commonly identified pathogen in patients with community-acquired pneumonia. 40% of isolated strains in France are of decreased sensibility to penicillin, two third being multiresistant to antibiotics. However, high doses of some beta-lactams are effective in vivo against the majority of circulating strains (MIC > 2 mg/L). For this reason according to French guidelines amoxicillin (3 g/day) is the first line recommended treatment. Telithromycin is an alternative, or ceftriaxone (1 g/day) in more severe cases. If the level of resistance increases (MIC > 4 mg/L) guidelines would be revisited. Effectiveness of pneumococcal vaccination has been confirmed in cases of bacteriemic pneumococcal pneumonia (elderly patients included). Vaccine is recommended among persons with comorbiditie(s) and 65 years old population.
Insights
Community-acquired pneumonia caused by Streptococcus pneumoniae is common. High-dose amoxicillin is recommended despite some penicillin resistance, with vaccination advised for high-risk groups.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Context:
- Streptococcus pneumoniae is a leading cause of community-acquired pneumonia (CAP).
- 40% of S. pneumoniae strains in France show decreased penicillin susceptibility, with two-thirds being multidrug-resistant.
- High-dose beta-lactams remain effective against most circulating strains.
Purpose:
- To outline current treatment guidelines for S. pneumoniae CAP in France.
- To discuss antibiotic resistance trends and their implications for treatment.
- To highlight the role of pneumococcal vaccination in prevention.
Summary:
- French guidelines recommend high-dose amoxicillin (3 g/day) as first-line CAP treatment due to in vivo effectiveness.
- Telithromycin and ceftriaxone (1 g/day) are alternatives for severe cases or increasing resistance (MIC > 4 mg/L).
- Pneumococcal vaccination is proven effective, especially in bacteremic pneumonia, and recommended for individuals with comorbidities and those aged 65+.
Impact:
- Informs clinical practice regarding appropriate antibiotic selection for CAP.
- Emphasizes the importance of monitoring antibiotic resistance patterns.
- Promotes vaccination strategies to reduce the burden of pneumococcal pneumonia.